loading
Schlusskurs vom Vortag:
$1.75
Offen:
$1.75
24-Stunden-Volumen:
653.10K
Relative Volume:
0.35
Marktkapitalisierung:
$151.39M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.83M
KGV:
-2.1709
EPS:
-0.79
Netto-Cashflow:
$-20.87M
1W Leistung:
+6.52%
1M Leistung:
+3.31%
6M Leistung:
+467.32%
1J Leistung:
+274.70%
1-Tages-Spanne:
Value
$1.68
$1.75
1-Wochen-Bereich:
Value
$1.61
$1.81
52-Wochen-Spanne:
Value
$0.2223
$3.83

Cognition Therapeutics Inc Stock (CGTX) Company Profile

Name
Firmenname
Cognition Therapeutics Inc
Name
Telefon
412-481-2210
Name
Adresse
2500 WESTCHESTER AVE, PURCHASE
Name
Mitarbeiter
25
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-08
Name
Neueste SEC-Einreichungen
Name
CGTX's Discussions on Twitter

Vergleichen Sie CGTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CGTX
Cognition Therapeutics Inc
1.715 154.48M 0 -22.83M -20.87M -0.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
438.92 112.15B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
699.61 73.91B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
417.54 56.81B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
892.07 55.46B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
193.97 41.92B 447.02M -1.18B -906.14M -6.1812

Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-19 Hochstufung B. Riley Securities Neutral → Buy
2024-07-30 Herabstufung Cantor Fitzgerald Overweight → Neutral
2021-11-03 Eingeleitet B. Riley Securities Buy
2021-11-03 Eingeleitet Oppenheimer Outperform

Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten

pulisher
Dec 05, 2025

Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? - Yahoo Finance

Dec 05, 2025
pulisher
Dec 05, 2025

Cognition Therapeutics (NASDAQ:CGTX) Earns "Buy" Rating from HC Wainwright - MarketBeat

Dec 05, 2025
pulisher
Dec 05, 2025

Why retail investors pile into Cognition Therapeutics Inc. stock2025 Growth vs Value & Daily Momentum Trading Reports - Newser

Dec 05, 2025
pulisher
Dec 04, 2025

HC Wainwright & Co. Reiterates Cognition Therapeutics (CGTX) Buy Recommendation - Nasdaq

Dec 04, 2025
pulisher
Dec 04, 2025

CGTX Analyst Rating: HC Wainwright & Co. Maintains Buy Rating | - GuruFocus

Dec 04, 2025
pulisher
Dec 04, 2025

Why Cognition Therapeutics Inc. stock is favored by pension fundsJuly 2025 Closing Moves & Free High Return Stock Watch Alerts - Newser

Dec 04, 2025
pulisher
Dec 03, 2025

Cognition Therapeutics completes enrollment in expanded access program By Investing.com - Investing.com Nigeria

Dec 03, 2025
pulisher
Dec 03, 2025

Cognition Therapeutics completes enrollment in expanded access program - Investing.com India

Dec 03, 2025
pulisher
Dec 03, 2025

Cognition Therapeutics Says Zervimesine Expanded Access Program Reaches Full Enrollment - marketscreener.com

Dec 03, 2025
pulisher
Dec 03, 2025

Cognition Therapeutics (NASDAQ: CGTX) sets FDA Type C meeting on Phase 3 DLB - Stock Titan

Dec 03, 2025
pulisher
Dec 01, 2025

Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug By Investing.com - Investing.com Nigeria

Dec 01, 2025
pulisher
Dec 01, 2025

Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug - Investing.com

Dec 01, 2025
pulisher
Dec 01, 2025

Cognition Therapeutics outlines phase 3 Alzheimer's plan at CTAD - marketscreener.com

Dec 01, 2025
pulisher
Dec 01, 2025

Cognition Therapeutics Outlines Phase 3 Alzheimer's Plan at CTAD - TradingView

Dec 01, 2025
pulisher
Dec 01, 2025

Cognition Therapeutics, Inc. Plans to Align with EMA on Alzheimer's Disease Strategy for Zervimesine at February 2026 Meeting - Quiver Quantitative

Dec 01, 2025
pulisher
Dec 01, 2025

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference - marketscreener.com

Dec 01, 2025
pulisher
Dec 01, 2025

Cognition Therapeutics (NASDAQ: CGTX) maps Phase 3 AD trial after 95% decline slowdown - Stock Titan

Dec 01, 2025
pulisher
Nov 28, 2025

Cognition Therapeutics Inc Stock Analysis and ForecastConsumer Goods Stocks & Affordable Market Investment - earlytimes.in

Nov 28, 2025
pulisher
Nov 27, 2025

Cognition Therapeutics Inc. (CGTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 27, 2025
pulisher
Nov 27, 2025

How Cognition Therapeutics Inc. stock reacts to oil pricesEarnings Recap Report & Free Real-Time Volume Trigger Notifications - BỘ NỘI VỤ

Nov 27, 2025
pulisher
Nov 24, 2025

Q1 Earnings Forecast for CGTX Issued By B. Riley - MarketBeat

Nov 24, 2025
pulisher
Nov 23, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Nov 23, 2025
pulisher
Nov 21, 2025

Cognition Therapeutics: A High-Stakes Bet On A Single DrugWhy I Hold (NASDAQ:CGTX) - Seeking Alpha

Nov 21, 2025
pulisher
Nov 21, 2025

B. Riley Securities Reiterates Cognition Therapeutics (CGTX) Buy Recommendation - Nasdaq

Nov 21, 2025
pulisher
Nov 21, 2025

Cognition Therapeutics (CGTX) Sees Analyst Price Target Boost | CGTX Stock News - GuruFocus

Nov 21, 2025
pulisher
Nov 21, 2025

B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating - marketscreener.com

Nov 21, 2025
pulisher
Nov 20, 2025

Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference - The Manila Times

Nov 20, 2025
pulisher
Nov 20, 2025

Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Speak at Annual Piper Sandler Healthcare Conference - Quiver Quantitative

Nov 20, 2025
pulisher
Nov 20, 2025

Cognition Therapeutics (Nasdaq: CGTX) CEO Talk at 37th Piper Sandler Healthcare Conf - Stock Titan

Nov 20, 2025
pulisher
Nov 20, 2025

Cognition Therapeutics' (CGTX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 20, 2025
pulisher
Nov 20, 2025

Will Cognition Therapeutics Inc. stock beat EPS estimatesJuly 2025 PostEarnings & Safe Entry Trade Reports - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Can Cognition Therapeutics Inc. stock beat analyst upgradesEarnings Trend Report & AI Enhanced Trading Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

What analyst consensus says on Cognition Therapeutics Inc. stock - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Will Cognition Therapeutics Inc. stock pay special dividendsPortfolio Performance Report & Long-Term Growth Portfolio Plans - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

CGTX: HC Wainwright Reiterates Buy Rating and Price Target | CGT - GuruFocus

Nov 19, 2025
pulisher
Nov 19, 2025

How to use a screener to detect Cognition Therapeutics Inc. breakoutsTrade Volume Summary & High Win Rate Trade Alerts - newser.com

Nov 19, 2025
pulisher
Nov 18, 2025

Why Cognition Therapeutics Inc. stock appeals to dividend seekersIndex Update & Long-Term Growth Plans - newser.com

Nov 18, 2025
pulisher
Nov 17, 2025

Analyzing Cognition Therapeutics Inc. with multi timeframe charts2025 Biggest Moves & Fast Moving Market Watchlists - newser.com

Nov 17, 2025
pulisher
Nov 17, 2025

James M. O’Brien Appointed Chief Financial Officer at Mesoblast - GlobeNewswire Inc.

Nov 17, 2025
pulisher
Nov 16, 2025

Cognition Therapeutics Announces $30.1M Direct Offering - MSN

Nov 16, 2025
pulisher
Nov 16, 2025

Relative strength of Cognition Therapeutics Inc. in sector analysis2025 Stock Rankings & Community Consensus Stock Picks - newser.com

Nov 16, 2025
pulisher
Nov 16, 2025

Will earnings trigger a reversal in Cognition Therapeutics Inc.July 2025 Technicals & Real-Time Volume Triggers - newser.com

Nov 16, 2025
pulisher
Nov 15, 2025

Will Cognition Therapeutics Inc. stock benefit from upcoming earnings reports2025 Historical Comparison & Reliable Price Breakout Signals - newser.com

Nov 15, 2025
pulisher
Nov 15, 2025

Smart tools for monitoring Cognition Therapeutics Inc.’s price actionTrade Ideas & Risk Controlled Swing Trade Alerts - newser.com

Nov 15, 2025
pulisher
Nov 15, 2025

Is Cognition Therapeutics Inc. stock cheap at current valuationJuly 2025 Technicals & AI Driven Price Forecasts - newser.com

Nov 15, 2025
pulisher
Nov 15, 2025

Will Cognition Therapeutics Inc. stock benefit from commodity pricesTrade Entry Report & Fast Exit and Entry Strategy Plans - newser.com

Nov 15, 2025
pulisher
Nov 14, 2025

Why Cognition Therapeutics Inc. stock is a value investor pick2025 Bull vs Bear & Expert-Curated Trade Recommendations - newser.com

Nov 14, 2025

Finanzdaten der Cognition Therapeutics Inc-Aktie (CGTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$38.19
price down icon 1.15%
$95.83
price down icon 0.92%
$31.15
price down icon 2.33%
$96.74
price down icon 0.54%
biotechnology ONC
$321.94
price down icon 1.20%
$193.73
price down icon 1.33%
Kapitalisierung:     |  Volumen (24h):